< Back to previous page

Project

Nanobody-based approach to inhibit RAS activity by modultating its interactome

Our proposal represents a novel approach to block RAS activity. We will utilize the Nanobody platform to isolate high-affinity Nanobodies that facilitate or inhibit the complex of RAS with its upstream regulators. We will screen for Nanobodies that suppress the RAS pathway in melanoma cells with different mutational status of BRAF and NRAS. We will assess the mechanisme of RAS inhibition. We will next elucidate the potency of the generated Nanobodies in a preclinical setting using a set of short-term cultured melanoma cell lines.

Date:1 Jan 2019 →  31 Dec 2022
Keywords:melanoma cells, cancer therapy
Disciplines:Cancer therapy